These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 33202689)

  • 1. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
    Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
    Patel S; Armbruster H; Pardo G; Archambeau B; Kim NH; Jeter J; Wu R; Kendra K; Contreras CM; Spaccarelli N; Dulmage B; Pootrakul L; Carr DR; Verschraegen C
    PLoS One; 2024; 19(4):e0297531. PubMed ID: 38687774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
    Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
    Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
    Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
    Sobanko JF; Okman J; Miller C
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
    Keating GM
    Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
    Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
    Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
    Abidi A
    Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.
    Dessinioti C; Plaka M; Soura E; Mortaki D; Papaxoinis G; Gogas H; Stratigos AJ
    Oncologist; 2019 Aug; 24(8):e755-e764. PubMed ID: 31073024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.